Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 10/20 | 0.43 |
| ▸ | RXRA | P19793 | 10/20 | 0.43 |
| ▸ | RXRG | P48443 | 8/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.33 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11215834 | 0.88 | RXRB (0.50) | RXRBRXRARXRGBCL2L1BAD | |
| SCHEMBL21392983 | 0.83 | RXRB (0.52) | RXRBRXRARXRGMRGPRX4BCL2A1 | |
| SCHEMBL21392984 | 0.80 | ALDH1A1 (0.42) | RXRBRXRARXRGALDH1A1MEN1 | |
| SCHEMBL31565004 | 0.79 | RXRA (0.49) | RXRBRXRARXRGBCL2L1BAD | |
| SCHEMBL20456630 | 0.79 | RXRA (0.49) | RXRBRXRARXRGBCL2L1BAD | |
| SCHEMBL4622662 | 0.75 | RXRB (0.40) | RXRBRXRARXRGBCL2L1BAD | |
| SCHEMBL20469871 | 0.69 | RXRA (0.44) | RXRBRXRARXRGBCL2L1BAD | |
| SCHEMBL1025407 | 0.68 | RXRB (0.52) | RXRBRXRARXRGBCL2L1BAD | |
| SCHEMBL20506904 | 0.68 | BCL2A1 (0.40) | ALDH1A1MEN1KMT2ALMNABCL2A1 | |
| SCHEMBL21962435 | 0.67 | CXCR5 (0.43) | RXRBRXRARXRGBCL2L1BAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164495-B | Covalent targeting of E3 ligases | 加利福尼亚大学董事会 | 2025-04-22 | — | — | CN | disclosed |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | disclosed |
| US-12161648-B2 | Covalent targeting of E3 ligases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| EP-3863642-A1 | COVALENT TARGETING OF E3 LIGASES | The Regents of the University of California (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113164495-A | Covalent targeting of E3 ligase | 加利福尼亚大学董事会 | 2021-07-23 | — | — | CN | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12161648-B2 | Covalent targeting of E3 ligases | RNF114, RNF4, RNF168 | RXRB 2973/4885RXRA 2823/4885RXRG 2484/4885 |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | RXRB 1975/4885RXRA 2028/4885RXRG 1851/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | RXRB 2973/4885RXRA 2823/4885RXRG 2484/4885 |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | STUB1, XIAP, RBX1 | RXRB 3292/4885RXRA 3146/4885RXRG 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.